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A recent perspective published in Frontiers of Pharmacology by Salomone and Waeber
(2011) discussed the selectivity and speciﬁcity of sphingosine 1-phosphate (S1P) receptor
ligands. This perspective surveyed the use of various S1P receptor ligands and attempted
to reconcile a number of inconsistencies in the predicted biological outcomes: these were
interpreted as “off-target” effects. Therefore the perspective cautioned against the use of
these S1P receptor ligands. Here we highlight the complex pharmacology of S1P recep-
tors, which along with “inside-out” signaling might provide an alternative explanation for
“off-target” effects.
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S1P binds to ﬁve different GPCRs termed S1P1–5 that exhibit dif-
ferential coupling to various G-protein sub-types (Pyne and Pyne,
2010). The perspective by Salomone and Waeber (2011) focused
on three S1P receptor ligands, JTE-013, BML-241 (CAY10444),
and VPC23019. The major issues raised by these authors related
to the ﬁndings that JTE-013 (which has been characterized as
an S1P2 receptor antagonist; Osada et al., 2002; Ohmori et al.,
2003) inhibited not only the vasoconstrictor effect of S1P, but also
that of the prostanoid analog U46619, endothelin-1, or high KCl
(Salomone et al., 2008). In addition, BML-241 (which has been
characterized as an S1P3 receptor antagonist; Koide et al., 2002)
inhibits increases in intracellular calcium mediated by P2 receptor
or α1A-adrenoceptor stimulation and reduces α1A-adrenoceptor
stimulated contraction of mesenteric artery, while it failed to pre-
vent the S1P3-mediated reduction in forskolin-stimulated cyclic
AMP accumulation (Jongsma et al., 2006). Moreover, VPC23019
(characterized as an S1P1/3 antagonist; Davis et al., 2005) unex-
pectedly potentiated S1P-stimulated contraction in intact basilar
arteries (Salomone et al., 2008); a result confounded by the ﬁnding
that S1P-stimulated vasoconstriction was reduced in tissue from
S1P3 knockout mice. In addition, VPC23019 behaves as a par-
tial agonist in a S1P3 calcium mobilization assay (Jongsma et al.,
2009). These anomalies are used to suggest that “off-target” effects
should be seriously considered as caveats to conclusions drawn,
unless validated by siRNA knock down or genetic knock out of
the S1P receptor being studied. If applied at sufﬁcient concen-
trations, all small molecules are likely to have “off-target” effects.
The issue here is that for the ligands mentioned above, none of
the “off-targets” have been deﬁnitively identiﬁed, and we do not
knowwhether a sufﬁcient concentrationhas been reached. In addi-
tion, critical analysis requires deﬁning the precise GPCR ligand
pharmacology for these reagents before a deﬁnitive appraisal of
“off-target” effects can be made. In this regard, the pharmacol-
ogy of GPCRs is not simple, and is made more complicated by
the fact that an array of different conformational states of the
same receptor might exist, each of which might bind ligands with
markedly different afﬁnities. Moreover, the different conforma-
tional states of a GPCR might also be differentially coupled to
distinct G-proteins. Several examples of this critically important
complex ligand pharmacology are discussed here.
FTY720 (or ﬁngolimod) is an immunosuppressant that was
very recently licensed by the Food and Drug Administration and
the European Medicines Agency as Gilenya™. This sphingosine
analog is taken up by cells, phosphorylated by sphingosine kinase
2 (SK2) and released as FTY720 phosphate. FTY720 phosphate
binds to and activates S1P1, S1P3, S1P4, and S1P5, but not S1P2
(Brinkmann et al., 2010). FTY720 phosphate also induces a later
“functional antagonism” by promoting the polyubiquitination,
endocytosis, and proteasomal degradation of S1P1 (Gräler and
Goetzl, 2004), which creates S1P1 receptor null T-cells to induce
lymphopenia. In contrast, S1P1 receptors recycle in response to
S1P. Therefore, S1P and FTY720 phosphate do not appear to bind
to and stabilize the same conformation of S1P1. These different
conformational states are likely to exist in equilibrium, as binding
of FTY720 phosphate to a speciﬁc S1P1 conformationwill increase
its concentration by mass action such that the entire population of
S1P1 will be eventually degraded in response to FTY720phosphate,
and this is indeed the case (Figure 1A).
The concept that different conformational states of S1P recep-
tors might exist is very important in terms of explaining the
unusual pharmacology of receptor ligands that could otherwise be
interpreted as “off-target” effects. For instance, FTY720 phosphate
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FIGURE 1 | (A) Phosphorylation of FTY720 by sphingosine kinase 2 (SK2)
and release to induce down-regulation of S1P1. (B) and (C) Equilibrium
transition model showing the binding of S1P, FTY720 phosphate (FTY720P),
or VPC23019 (VPC) to the conformational states (denoted by different
shapes) of S1P3 coupled to different G-proteins. The positions of the
equilibrium in (B,C) will be affected by binding of S1P, FTY720P, or
VPC23019 to the different conformations of S1P3 but are not represented
here for simplicity. The ligands are shown in red.
binds to and activates a speciﬁc S1P3–Gi coupled receptor confor-
mation and inhibits S1P3–Gq coupled receptor signaling (Sensken
et al., 2008). These ﬁndings can be explained by a model in which
S1P3–Gq and S1P3–Gi are in equilibrium. Thus, FTY720 phos-
phate may act as a “biased agonist” by binding exclusively to the
S1P3–Gi conformation which would reduce the concentration of
the S1P3–Gq receptor conformation by mass action and thereby
inhibit S1P3–Gq signaling (Figure 1B). Therefore, it is possible
that BML-241 is also a “biased” agonist of the S1P3–Gi confor-
mation that regulates adenylyl cyclase and thus, an antagonist of
S1P3–Gq signaling. If this is the case, then one would not necessar-
ily expect BML-241 to prevent an S1P/S1P3-mediated inhibition
of forskolin-stimulated cyclic AMP accumulation.
We have evaluated the effect of BML-241 (CAY10444) on S1P2,
S1P3, and S1P4 each separately over-expressed in HTC4 cells. Our
ﬁndings demonstrate that BML-241 inhibited S1P/S1P3-mediated
calcium mobilization in a concentration-dependent manner with
a ∼80% inhibition at 10μM BML-241. BML-241 had no effect
on S1P-stimulated calcium responses mediated by S1P2 or S1P4
(Long et al., 2010a). Although, BML-241 is a low potency antago-
nist of S1P3, the extent to which it reduces S1P-stimulated calcium
mobilization inHTC4 cells over-expressing S1P3 is superior to that
reported by Koide et al. (2002). Further support for an action of
BML-241 on S1P3 was obtained by our ﬁndings that S1P stim-
ulation of ERK-1/2 in MCF-7 breast cancer cells is abolished by
BML-241 and this is recapitulated by siRNA knockdown of S1P3
(Long et al., 2010b). Interestingly, S1P stimulation of ERK-1/2 in
MCF-7 cells is reduced by pertussis toxin, indicating involvement
of S1P3–Gi (Sukocheva et al., 2006). This might suggest increased
complexity in the behavior of BML-241 which appears to antag-
onize a conformation of S1P3–Gi that is coupled to the ERK-1/2
pathway in MCF-7 cells.
BML-241 inhibits increases in intracellular calcium mediated
by P2 receptor or α1A-adrenoceptor stimulation in CHO cells and
reduces α1A-adrenoceptor stimulated contraction of mesenteric
artery (Jongsma et al., 2006). However, the possibility that stim-
ulation of these receptors activates sphingosine kinase (catalyzes
synthesis of S1P from sphingosine) to promote S1P synthesis and
release, which can then act on local S1P receptors (e.g., S1P3)
in the artery (termed “inside-out” signaling), cannot be excluded
at this time. Indeed, we have also shown that BML-241 inhibits
S1P- and anandamide-induced relaxation of endothelium intact
coronary artery vessels (by blocking the “inside-out” signaling
by S1P in response to anandamide). The latter is also reduced
by VPC23019 (Mair et al., 2010), while W146, an S1P1 selective
antagonist (Wamhoff et al., 2008) had no effect (Mair et al., 2010).
In addition to “inside-out” signaling, the alternative possibility
that P2 or α1A-adrenoceptors might form functional heterodimers
with S1P3 and that BML-241 induces allosteric effects on P2
or α1A-adrenoceptor-mediated signaling via S1P3 has not been
excluded.
JTE-013 (Ohmori et al., 2003) is widely used as a S1P2 antag-
onist in vitro and is effective in vivo, reducing streptozotocin-
induced apoptosis of pancreatic β cells and incidence of diabetes
(Imasawa et al., 2010) and IgE-triggered anaphylactic responses
(Oskeritzian et al., 2010). Both of these disease models are atten-
uated in SIP−/−2 mice, thereby supporting a role for this receptor
type, and the action of JTE-013 at S1P2. As pointed out by
Salomone andWaeber (2011), JTE-013 inhibited the speciﬁc bind-
ing of radiolabeled S1P with an IC50 of 17± 6 and 22± 9 nM in
CHOcells over-expressinghumanor rat recombinant S1P2 respec-
tively, and had no effect on S1P1 or S1P3 at concentrations in
excess of 10μM (Ohmori et al., 2003).We conﬁrmed that JTE-013
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inhibited S1P-stimulated calcium mobilization with an IC50 of
∼1μM in HTC4 cells over-expressing S1P2, with no signiﬁcant
effect on S1P-stimulated calcium mobilization in HTC4 cells over-
expressing S1P3 at concentrations as high as 10μM (Long et al.,
2010a). However, we also demonstrated that JTE-013 is not spe-
ciﬁc for S1P2, and inhibits S1P-stimulated calcium mobilization in
HTC4 cells over-expressing S1P4 with a Ki of 237 nM (Long et al.,
2010a). Moreover, S1P stimulation of ERK-1/2 in MDA-MB-453
breast cancer cells, which express endogenous S1P2 and S1P4, was
inhibited by JTE-013 (10μM) and this was recapitulated by siRNA
knockdown of S1P4, but not S1P2 (Long et al., 2010a).
The ability of JTE-013 to antagonize S1P4 might provide an
alternative explanation for the ﬁnding that JTE-013 inhibits S1P-
induced vasoconstriction in SIP−/−2 mice (Salomone and Waeber,
2011). Although S1P4 is reported to have a rather restricted tissue
distribution conﬁned to immune cells, this may not be the case
as evidenced by its expression in breast cancer cells (Long et al.,
2010a) or, alternatively,heterogenous tissue preparationsmay con-
tain inﬂammatory cells that release vasoconstrictors in response
to S1P, mediated by S1P4. JTE-013 also inhibited prostanoid-,
endothelin 1-, and KCl-induced contraction, the latter suggest-
ing perturbation of L-type calcium channel activity (Salomone
et al., 2008). However, vasoconstriction of the basilar artery to
prostanoid and KCl is reduced in SK1−/− mice (Salomone et al.,
2010). Furthermore, we found that JTE-013 had no signiﬁcant
inhibitory effect on S1P-stimulated calciummobilization inHTC4
cells over-expressing S1P3 (Long et al., 2010a) suggesting that
JTE-013 (10μM) has no activity on S1P3 or calcium signaling
down-stream of S1P receptors.
To highlight the complexity of the pharmacology of S1P recep-
tor ligands, we point to SB649146 (Waters et al., 2006; Pyne and
Pyne, 2008). SB649146 is a protean agonist of S1P1 (see Kenakin,
2001 for review of protean agonism). SB649146 exhibits inverse
agonism by reducing S1P1-mediated Gi activation, competitive
antagonism of S1P (displaces dihydro S1P (an S1P1 agonist) and
inhibits S1P-stimulated activation of ERK-1/2 in airway smooth
muscle cells) and is a partial agonist when used alone, e.g.,
SB649146 weakly stimulates the pertussis toxin-sensitive ERK-
1/2 pathway in airway smooth muscle cells (Waters et al., 2006).
The effect of SB649146 is mediated by binding to S1P1 in airway
smooth muscle cells because treatment of these cells with an anti-
sense oligonucleotide speciﬁc for S1P1 abolished S1P-stimulated
activation of ERK-1/2 (Waters et al., 2003). SB649146 also induces
endocytosis of a relatively small pool of S1P1 in airway smooth
muscle cells, consistent with a partial agonistic effect on S1P1,
but inhibits S1P-stimulated endocytosis/signaling of S1P1 (Waters
et al., 2006).
The action of VPC23019 (which was initially described as an
S1P1/3 antagonist, Davis et al., 2005) as an S1P3 agonist on cal-
cium signaling (Jongsma et al., 2009) might also be explained
by complexities in GPCR pharmacology. In this regard, Jongsma
et al. (2009) have demonstrated that VPC23019 reduces forskolin-
stimulated cAMPaccumulation inCHOcells over-expressing S1P3
suggesting that it might function as an agonist by binding to
and stabilizing the S1P3–Gi conformation. Moreover, VPC23019
stimulated calcium mobilization, a response that was sensitive
to pertussis toxin and thus possibly also mediated by S1P3/Gi
and a Giβγ-regulated PLCβ2-dependent mechanism (Figure 1C).
Crucially, the effect of VPC23019 on S1P-stimulated calcium
mobilization (to establish whether it inhibits S1P3–Gq-mediated
calcium signaling) was not tested. Therefore, the potentiating
effect of VPC23019 on S1P-induced vasoconstriction described by
Salomone and Waeber (2011) might also be explained by biased
agonism at S1P3–Gi and stimulation of PLCβ2/calcium signaling,
although this requires formal investigation. This interpretation
is not at odds with the data obtained using SIP−/−3 mice, where
S1P-stimulated calcium mobilization by both Gi and Gq signaling
routes would be ablated.
Davis et al. (2005) demonstrated that VPC23019 competitively
inhibited S1P-stimulated GTPγS binding in membranes from
HEK 293T cells transiently over-expressing S1P3 together with
mutated C352F mutated Gi2α, β1, and γ2. However, it should
be stated that Davis et al. (2005) did not observe any agonistic
effect of VPC23019 in their assay system. In addition, VPC23019
competitively antagonized S1P-stimulated calcium mobilization
in T24 cells stably over-expressing S1P3 (Davis et al., 2005) and
displaced radiolabeled S1P binding to S1P1 or S1P3 receptors in
HEK 293T cells. Therefore, differences found in the two studies
appear to be centered around the S1P3 pharmacology in the dif-
ferent assay systems used. TY-52156, a selective S1P3 antagonist
restores coronary blood ﬂow that was reduced by S1P, and inhibits
Rho dependent activation and calcium signaling (Murakami et al.,
2010), suggesting that it does not discriminate betweenS1P3 recep-
tor conformations. This contrasts with VPC23019 which has no
effect on coronary ﬂow (Murakami et al., 2010), possibly because
it might not antagonize S1P3-Rho conformational signaling. In
the same study, VPC23019 was shown to inhibit Eu-GTP binding
in membranes from cells over-expressing S1P3. It should also be
noted that TY-52156 has been used in only one study to date and
is also an S1P4 antagonist (Murakami et al., 2010). VPC23019
is a phosphorylated lipid and is therefore a possible substrate
for lipid phosphate ectophosphatases (LPP, for review see Pyne
et al., 2005). Therefore, LPP activity might limit availability of
VPC23019 at S1P receptors, and this might account for differ-
ences in pharmacology in certain cellular systems dependent on
the expression level of LPP. VPC23019 is also a full agonist of
S1P4 and a partial agonist of S1P5 (Davis et al., 2005) and this
may complicate interpretation of its effects in heterogenous tissue
preparations.
Salomone and Waeber (2011) also state that “off-target” effects
of FTY720 are not likely relevant to the clinical action of FTY720
(via FTY720 phosphate), which occur at nanomolar concentra-
tions in terms of inducing lymphopenia. This is compared with
micromolar concentration effects of FTY720 on SK1 (Tonelli et al.,
2010), ceramide kinase (Lahiri et al., 2009), 14-3-3 protein (Wood-
cock et al., 2010), acid sphingomyelinase (Dawson and Qin, 2011),
and phospholipase A2 (Payne et al., 2007). There are two impor-
tant points here. FTY720 has to be taken up into cells, so that it
can be phosphorylated by SK2 to form FTY720 phosphate. The
Km of SK2 for FTY720 is 18.2μM (Billich et al., 2003). Thus, we
suspect that FTY720 has to be concentrated by the cell to bring
its concentration into the micromolar substrate range so that it
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can be used by SK2 to form FTY720 phosphate. Notably, the Ki
for SK1 inhibition by FTY720 is 2μM (Lim et al., 2011) and this
is therefore close to the concentration of FTY720 that might be
expected to accumulate within cells from an extracellular nM con-
centration. Second,FTY720 and FTY720 phosphate have opposing
actions. Thus, the treatment of human cancer cells (MCF-7,MDA-
MB-231, and Sk-Br-3 cells) with FTY720 inhibits growth, activates
JNK, and transiently inhibits ERK-1/2 activation with no effect on
p38MAPK inMCF-7 cells. In contrast, FTY720 phosphate induces
growth of these cells (Nagaoka et al., 2008). FTY720 demonstrates
signiﬁcant anti-cancer activity in vivo, and apoptosis of cancer
cells, and this is therefore likely to be directly related to inhibi-
tion of SK1, an enzyme which is known to play a critical role in
promoting cancer cell survival (Pyne and Pyne, 2010). Therefore,
one can legitimately question whether SK1, PLA2, etc., are indeed,
“off-targets.”
Clearly, screening is required to test the selectivity and speci-
ﬁcity of ligands for receptors and enzymes, related targets and
“off-targets.” However, in the absence of identiﬁed “off-targets”
that can explain the observed pharmacology, the alternative possi-
bilities centered around the complexities of GPCR pharmacology
must also be considered. Therefore, the purpose of this perspective
is to bring these issues to the attention of the research commu-
nity so that GPCR pharmacology versus “off-target” effects can
be tested experimentally in the future. In addition, Salomone and
Waeber (2011) cite many studies concerning the use of JTE-013,
BML-241, and VPC23019 that have not been validated by genetic
deletions or eliminations. However, lack of validation of an effect
of a given S1P receptor ligand does not immediately invalidate the
conclusion drawn. Moreover, genetic deletions or siRNA elim-
ination are also not without “off-target” effects, especially as
GPCRs exist in constitutively active states and/or are regulated
by autocrine ligands to induce signaling pathways that regulate
gene expression. Some of the genes regulated by genetic dele-
tions or eliminations of GPCRs might induce an effect which
is not recapitulated by an acute action of an antagonist. We
ascribe to a combined approach using pharmacological ligands
andmolecular tools to validate speciﬁcity (Waters et al., 2003; Long
et al., 2010a,b). However, a wider panel of receptor ligands is also
required to add power to the validation process and one should be
aware of limitations in interpretation of molecular approaches
if complexities in the GPCR ligand pharmacology are not
fully deﬁned.
In our opinion, multiple assays should be used (e.g., ligand
binding, GTPγS binding, calcium, cAMP, β-arrestin, and ERK-1/2
activation) to characterize competitive antagonism, biased ago-
nism, and protean agonism. The knowledge of which signaling
effectors are controlled by the various conformational states of
a given S1P receptor should then inform on the appropriate use
of deﬁned pharmacological agents to interrogate a biological sys-
tem. This approach should also enhance information gained from
genetic knockout or elimination studies.
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